Novel Agents in the Treatment of Lung Cancer: Assessing Opportunities for Combination Therapy
Online CME Activity
This activity is published in the journal Journal of Thoracic Oncology, Vol 3, No 6, Suppl 2, pp S107-S112, Jun 2008: "Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy "
Up to 3 hours of AMA PRA Category 1 Credit™
Release date: June 2008 Valid through: July 2009
Course Material: CME Activity - PDF
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This activity is designed to meet the educational needs of medical oncologists and other medical professionals who assess, treat and counsel lung cancer patients.
Educational Objectives
Following completion of this activity, participants should be able to: list the principal drug classes that are currently most clinically advanced for the treatment of lung cancer; discuss the key clinical data or clinical status for each principal class of agents; and discuss the rationale for and against combination therapy in lung cancer.
Educational Need
Several classes of novel agents are now available or advancing in the clinic for the treatment of lung cancer, each designed to affect a specific lung cancer growth pathway. As targets and agents have proliferated and advanced, so too has data showing that individual tumors differ biologically, and some tumors appear to succeed by using more than one pathway, or by switching pathways. This information raises important new issues for the assessment and integration of novel agents in lung cancer treatment. Oncologists and other health care professionals who assess, treat and counsel lung cancer patients need to be aware of the key data supporting the advancement of each class of agents and the issues and opportunities for their use as single agents and the development of combination therapies.
Sponsorship and Accreditation
This enduring journal CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. (InforMEDical). InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
This program is supported by educational grants provided by: Genentech, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Inc., Bayer Healthcare Pharmaceuticals and Onyx, Inc., Boehringer Ingelheim and EMD Serono
Credit Designation
InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
George Blumenschein: Bayer: consultant. Jeffrey Engelman: Hoffmann-La Roche: advisory board. Igor Espinoza-Delgado: Nothing to disclose. Ramaswamy Govindan: sanofi-aventis: Speakers’ Bureau; Eli Lilly: research support, Speakers’ Bureau; Genentech: research support, Speakers’ Bureau; Pfizer: research support. Jeff Hanke: AstraZeneca: employee. Nasser Hanna: Bayer: consulting; Bristol-Myers Squibb: research grant; Eli Lilly: research grant, Speakers’ Bureau; Genentech: research grant. John Heymach: AstraZeneca: advisory board, research support; Pfizer: advisory board, research support. Fred Hirsch: AstraZeneca: consultant, research support; Bristol-Myers Squibb/ImClone: consultant; Boehringer Ingelheim: consultant; Genentech: research support; Lilly Oncology: consultant; OSI Pharmaceuticals: research support; Merck: research support; Pfizer: consultant; Hoffmann-La Roche: consultant. He holds a patent for methods of prediction of clinical outcomes of EGFR inhibitors for cancer patients. . Rakesh Jain: AstraZeneca: consultant, research grant; DTax: consultant; Enrlight-TRV: Scientific Advisory Board, consultant; Pfizer: consultant. Pasi Janne: AstraZeneca: honorium; Genentech: research support; Genzyme: royalties for intellectual property; Hoffmann-La Roche: honorarium. Rogerio Lilenbaum: AstraZeneca: consultant; Eli Lilly: consultant, honorarium; Genentech: consultant, research support; sanofi-aventis: consultant, research support. Thomas Lynch: AstraZeneca: consultant, honorarium; Boehringer Ingelheim: advisor; Eli Lilly: consultant, honorarium; Genentech: consultant, honorarium; Genzyme: royalty; ImClone: advisor; Millennium: consultant; OSI: consultant, honorarium; sanofi-aventis: advisor, honorarium; Telik: consultant. Ronald Natale: AstraZeneca: research grant; Eli Lilly: research grant, Speakers’ Bureau; Genentech/OSI: research grant, Speakers’ Bureau; Millennium: research grant; Pfizer: research grant. Gregory Riely: Boehringer Ingelheim: advisory board, honorarium; Genentech: advisory board. Lecia Sequist: Nothing to disclose. Geoffrey Shapiro: AstraZeneca: advisory board, research grant; Novartis: research grant. Alice Shaw: Nothing to disclose. Frances Shepherd: Merck: consultant; Biomira: consultant. Mark Socinski: Pfizer: research support. A. Greg Sorensen: Adnexus: consultant, research support, Speakers’ Bureau; AstraZeneca: consultant, research support, Speakers’ Bureau; EPIX Medical: equity position, medical advisor; consultant, research support, Speakers’s Bureau; General Electric: consultant, research support, Speakers’ Bureau. GlaxoSmithKline: consultant, research support, Speakers’ Bureau. Merck: consultant, research support, Speakers’ Bureau. Novartis: consultant, research support, Speakers’ Bureau. Pfizer: consultant, research support, Speakers’ Bureau. Schering: consultant, research support, Speakers’ Bureau. Siemens: consultant, research support, Speakers’ Bureau. Transkaryotic: consultant, research support, Speakers’ Bureau. Heather Wakelee: Eli Lilly: research support; Genentech: research support; sanofi-aventis: advisory board. Aaron Weitzman: Genentech: employee.